Role of betulinic acid derivative SH-479 in triple negative breast cancer and bone microenvironment

LIANG TANG1*, SHU JUN LV2*, ZHIPENG WU1*, MING QIAN1, YUDUO XU1, XIN GAO1, TAO WANG1, WEN GUO3, TIANHUI HOU1, XIU LI1, ZHENXI LI1, JIAN ZHAO1, JIANRU XIAO1 and HAIFENG WEI1

1Spine Tumor Center, Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003; 2Department of Orthopedics, Hai'an People's Hospital, Jiangsu, Hai'an 226600; 3Department of Orthopedics, Taizhou People's Hospital, Jiangsu, Taizhou 225300, P.R. China

Received September 3, 2020; Accepted April 8, 2021

DOI: 10.3892/ol.2021.12866

Abstract. Breast cancer has a high prevalence in the general population and is often associated with bone metastasis. Specific therapeutic targets are missing for triple negative breast cancer (TNBC), which presents some immunogenic characteristics. Betulinic acid (BA) has been reported to have some anti-tumor properties, and its modified derivative SH-479 was demonstrated to inhibit TNBC bone metastasis. The present study aimed to investigate the effect of the BA derivative SH-479 on breast cancer and bone microenvironment. The effect of BA and its derivative SH-479 on MDA-MB-231 cell proliferation was determined with the MTS method. The cytotoxicity effect of SH-479 was evaluated using the Live and Dead assay. Cell microfilament changes were observed by F-actin staining. The effects of SH-479 on PARP protein expression and cell cycle were detected by western blotting and flow cytometry, respectively. The migratory ability of breast cancer cells treated with SH-479 was determined by migration assay. The effect of SH-479 on osteoclast differentiation induced by breast cancer cells was observed using the osteoclast differentiation assay and tartrate-resistant acid phosphatase staining. The effects of SH-479 on T lymphocytes and bone marrow-derived suppressor cells (MDSCs) in bone marrow from mice were observed by flow cytometry. The results demonstrated that SH-479 significantly inhibited the proliferation of the TNBC cell line MDA-MB-231 at lower concentrations but had no significant effect on normal cells and other types of breast cancer cells for the same concentration. Furthermore, SH-479 significantly interfered with actin microfilaments in breast cancer cells but had no effect on cell apoptosis and cell cycle. In addition, SH-479 inhibited the migratory ability of breast cancer cells and the differentiation of osteoclasts induced by breast cancer cells. In bone marrow immune microenvironment, addition of SH-479 could promote the proliferation of CD4+T lymphocytes and inhibit the proliferation of MDSCs. Taken together, the findings from this study demonstrated that SH-479 inhibited the activity and migratory ability of TNBC cells and the differentiation of osteoclasts induced by TNBC and affected the bone marrow immune microenvironment. SH-479 may therefore inhibit breast cancer metastasis to bones, indicating that SH-479 may be considered as a promising drug to inhibit bone metastasis in patients with breast cancer.

Introduction

Breast cancer is the most common female malignant tumor worldwide (1). Breast cancer can be divided into different subtypes according to cancer cell morphology and cell surface receptors, including Luminal type, human epidermal growth factor receptor 2 (HER2) type and triple negative breast cancer (2). Bone tissue is the most common site of breast cancer metastasis (3). Depending on the stages of breast cancer, the incidence of bone metastasis can reach 75% (4-6). Even early breast cancer has a 22% incidence of bone metastasis, and bone metastases occurs after ~8.4 years (7). The average overall survival rate for patients with breast cancer and bone metastasis is only 40 months (6).

Triple negative breast cancer (TNBC) is a specific subtype of breast cancer, which is characterized by a negative expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor (8,9). TNBC is more common in premenopausal women, and the age of onset is earlier than other types of breast cancer (10). TNBC is an independent clinicopathological type with strong invasiveness and poor prognosis. TNBC accounts for 10-20% of all breast cancers (11,12). Although this subtype of breast cancer is sensitive to chemotherapy (13), the clinical outcome and prognosis remain poor following standard treatment. Because patients with TNBC have negative expression for ER, PR...
and HER2, they cannot benefit from endocrine therapy and targeted therapy against HER2. Immunotherapy, which is a new method to treat tumors, has been gradually applied to the treatment of TNBC. For example, suppression against immune checkpoint PD-L1 can be used as a therapeutic approach (14). At present, TNBC has become a new hotspot of breast cancer research in the world.

Numerous active principles from Chinese herbal medicines have been found to have anti-cancer effects, and some have been approved by the Food and Drug Administration (15). For example, betulinic acid (BA) has been widely studied because of its safety and effect on numerous biological functions. Previous studies have demonstrated that BA has some therapeutic effects, including anti-inflammation (16,17) and treatment of diabetes by selective activation of Tgrr5 receptors (18,19). BA and its derivative compounds show antiplasmodial activity against chloroquine-resistant Plasmodium falciparum parasites (20). BA also has a certain therapeutic effect on tumors, and it was reported that it can promote the apoptosis and regulate the cell cycle of glioma cancer cells (21,22).

Because of the poor solubility and the low bioavailability of BA, 35 BA derivatives were obtained and the compound 20 (SH-479) inhibitory effects of RANKL-induced osteoclastogenesis of these derivatives was evaluated in TNBCs. Compound 20 has been reported to exhibit a dramatic increase in inhibitory potency compared with BA (23). In order to maintain BA activity, the water solubility of the derivatives was enhanced and the bioavailability of the derivatives was subsequently improved.

The activity and migratory ability of tumor cells can directly affect the occurrence of distant metastasis. Tumor cells are compared to the “seeds” of plants. Only when they reach the proper “soil”, which is the organs with metastatic lesions, can the seeds grow, and metastasis occurs (24). Bone marrow microenvironment plays an important role in the development of bone metastasis. Osteoclasts can decompose bone, release increased growth factors and promote the proliferation of tumor cells, ultimately forming a vicious circle (25). Simultaneously, immunosuppressive cells are recruited into the bone marrow microenvironment, such as Treg and bone marrow-derived suppressor cells (MDSCs) (26,27). Immune cells in the bone marrow microenvironment are inhibited when bone metastasis occurs, promoting tumor cell immune escape. Breast cancer, lung cancer and multiple myeloma inhibit CD8+T lymphocytes by recruiting MDSC and thus promote tumor development (28). The present study aimed to investigate the effect of the BA derivative SH-479 on breast cancer and bone microenvironment.

Materials and methods

Cell culture. The cell lines MDA-MB-231, MCF-7, SKBR3, MCF-10A and RAW264.7 were purchased from the Cell Bank of Type Culture Collection of The Chinese Academy of Sciences. MDA-MB-231, MCF-7 and SKBR3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (HyClone; Cytiva) and 100 U/ml penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.). MCF-10A were cultured in DMEM/F12 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 5% horse serum (Invitrogen; Thermo Fisher Scientific, Inc.), 10 µg/ml insulin (Invitrogen; Thermo Fisher Scientific, Inc.), 20 ng/ml epidermal growth factors (Invitrogen; Thermo Fisher Scientific, Inc.), 100 ng/ml cholela toxin (Sigma-Aldrich; Merck KGaA) and 0.5 µg/ml hydrocortisone (Invitrogen; Thermo Fisher Scientific, Inc.). RAW264.7 were cultured in α-minimum essential medium (α-MEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS and 100 U/ml penicillin-streptomycin. All cells were placed at 37°C in a humidified incubator containing 5% CO₂.

Cell viability assay. A total of 35 BA derivatives were obtained and the compound 20 was named SH-479. To obtain SH-479, a solution of BA (2.28 g, 5 mmol) in tetrahydrofuran (10 ml) was added dropwise to a stirring solution of 2-iodoxybenzoic acid (2.1 g, 7.5 mmol) in DMSO (30 ml) at 23°C. The reaction mixture was stirred for 2 h at 23°C and then diluted with ethyl acetate (AcOEt; 30 ml) and washed with brine (50 ml). The organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography (petroleum ether/AcOEt; 8/1 v/v) to give compound 1 (2.05 g, 90%) as a white solid (melting point, 251-253°C) (23). The concentrations used for BA are 0-25 µM. The concentrations used for SH-479 are 0-10 µM. The durations of the treatments was 72 h. The effect of BA and SH-479 on cell viability was determined using the MTS method following the instructions from the Cell Titer 96 Aqueous One Solution Cell Proliferation assay (Promega Corporation). Briefly, the cell density was adjusted to 10³/ml. The cell suspension was inoculated into 96-well plates at 100 µl/well and cultured overnight. Cells were treated with BA (0-25 µM) and SH479 (0-10 µM) and cultured for 72 h. MTS solution (20 µl) was added to each well and incubated for 4 h. The absorbance was read at 490 nm on a VERSA max microplate reader (Molecular Devices, LLC).

Live and dead assay. The cytotoxicity of SH-479 on MDA-MB-231 cells was assessed using Live and Dead assay kit (Invitrogen; Thermo Fisher Scientific, Inc.) as previously described (29). Briefly, 2,500 cells were seeded into 96-well plates. After cell attachment, the cells were treated with SH479 (0-10 µM) for 30 h. Cells were stained with Live and Dead reagent (5 µM ethidium homodimer and 5 µM propidium iodide) and then incubated at 37°C for 45 min. Live and dead cells were observed under a fluorescence microscope (magnification, x20).

F-actin assay. MDA-MB-231 were seeded into 96-well plates (5,000 cells/well) and treated with SH-479 (0-10 µM). After 3 days, cells were fixed with 4% paraformaldehyde for 10 min at room temperature and subsequently incubated for 5 min at room temperature with PBS containing 0.1% Triton-X 100 and with rhodamine conjugated phalloidin (cat. no. R415; 1:200 in PBS; Thermo Fisher Scientific, Inc.) for 30 min in the dark at room temperature. F-actin staining was observed under an inverted fluorescence microscope (Olympus Corporation; magnification, x40).
Western blotting. MDA-MB-231 cells were lysed on ice using RIPA buffer (cat. no. R0278; Sigma-Aldrich; Merck KGaA). Protein concentration was evaluated using the BCA method. Proteins (30 µg) were separated by 10% SDS PAGE and transferred onto PVDF membranes. After blocking for 1 h in 5% skimmed milk dissolved in PBS, membranes were incubated with primary antibodies against cyclin E (cat. no. SC248 1:500 Santa Cruz Biotechnology, Inc.), PARP (cat. no. AY 0276; 1:1,000; Abways Technology, Inc.), cleaved PARP (cat. no. CY5035; 1:500; Abways Technology, Inc.) and β-actin (cat. no. A5441; 1:5,000; Sigma-Aldrich; Merck KGaA) at 4˚C overnight. The membranes were washed three times with PBST (0.1% Tween) and incubated with infrared dye-labeled secondary antibody (LI-COR Biosciences) for 1 h at room temperature. The signal on the membrane was visualized using LI-COR Odyssey System.

Cell-cycle analysis. The effect of SH-479 on cell cycle was determined by flow cytometry. Briefly, cells were serum-starved for 24 h and treated with 5 µM SH-479 for 12 h. Subsequently, cells were fixed in 70% ethanol at 4˚C overnight. Cells were stained with propidium iodide (cat. no. R37108; Thermo Fisher Scientific, Inc.) for 30 min at room temperature. Cell cycle analysis was conducted using a flow cytometry (Becton, Dickinson and Company). The software used for the analysis was FlowJo VX10.0 (FlowJo LLC).

Migration assay. The migration assay was performed in Boyden chambers (Corning Inc.). MDA-MB-231 cells (80,000) were suspended in 100 µl DMEM medium and treated with SH-479 (0-5 µM). The mixture was added to the upper well of Boyden chambers. DMEM medium (600 µl) supplemented with 2% FBS was added in the lower chamber. After 8 h incubation, cells that have migrated to the lower chambers were counted. Cells were then suspended in 100 µl DMEM medium and treated with 10 µM SH-479 for 48 h at 37˚C in the 6 cm plate. After 48 h, one million cells were incubated with 0.5 µl antibody (CD3-FITC, cat. no. 100204; CD4-PerCP-Cy5.5, cat. no. 10043; CD8-APC, cat. no. 344722; CD11b-APC, cat. no. 101212; Ly6C-PerCP-Cy5.5, cat. no. 128012; Ly6G-PE, cat. no. 127608; BioLegend, Inc.) at 4˚C for 30 min. Cells were then washed with 2% PBS, and T cells and MDSCs (CD11b+) were detected by flow cytometry (Becton, Dickinson and Company). Results were analyzed using FlowJo VX 10.0 software (FlowJo LLC).

Statistical analysis. The data were expressed as the means ± standard deviation. Differences between two groups were determined using paired Student’s t-test. Comparisons between multiple groups were determined by one-way ANOVA followed by Dunnett’s post hoc test. All statistical analyses are performed using GraphPad Prism 5.0. (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Inhibitory effect of BA and SH-479 on the viability of breast cancer cells. The effect of BA (Fig. 1A) and the 35 BA derivatives on TNBC cell viability was assessed. Because only SH-479 showed a significant effect, the results from other BA derivatives were not presented. The results demonstrated that SH-479 (Fig. 1B) significantly inhibited the viability of MDA-MB-231 cells in a concentration-dependent manner after 72 h compared with the control group (Fig. 1D). However, the viability of MDA-MB-231 cells was significantly inhibited by more than 50% when higher concentration of BA was added (Fig. 1C).

SH-479 has an inhibitory effect on TNBC cell viability. When using drugs to treat tumors, the common side effects of drugs are toxicity to normal cells. The results showed that only 30% of MCF-10A viability was inhibited after SH-479 treatment (0.1-10 µM; Fig. 2A). Furthermore, SH-479 did not significantly inhibit the viability of the luminal type cell line MCF-7 and Her2 type cell line SKBR3 at low concentration (Fig. 2A). In addition, SH-479 had no effect on the morphology of the
normal breast tissue cells MCF-10 (Fig. 2B). However, when MDA-MB-231 cells were treated with SH-749, cells seemed to shrink and their morphology changed in a dose-dependent manner (Fig. 2B).

**SH-479 alters microfilaments in breast cancer cells.** The morphological changes of cell shrinkage might be caused by cell death or by structural changes within the cells. The results demonstrated that after 30 h treatment with SH-479 (0.1-10 µM), MDA-MB-231 cells presented morphological shrinkage, although no cell death was observed. Green fluorescence represents living cells and red fluorescence represents dead cells (Fig. 3A). After 72 h treatment with SH-479 (0.1-10 µM), the microfilaments of MDA-MB-231 cells were altered according to F-actin staining. The red fluorescence indicates the cytoskeleton and the blue

---

**Figure 1.** Structure of BA and SH-479 and their effect on breast cancer cells. Human triple negative breast cancer cells MDA-MB-231 were treated with BA and SH-479 for 72 h with indicated concentrations. (A) Chemical structure of BA. (B) Chemical structure of SH-479. (C) Effect of BA and (D) SH-479 on MDA-MB-231 cell viability determined by MTS assay. Data were presented as the means ± standard deviation of three individual experiments. **P<0.01 and ***P<0.001. BA, betulinic acid.

**Figure 2.** SH-479 inhibits the proliferation of MDA-MB-231 cells. Normal breast cells MCF-10A and breast cancer cells were cultured with SH-479 for 72 h with indicated concentrations. (A) Effect of SH-479 on MCF-10A cell viability by MTS assay. Effect of SH-479 on MCF-7 and SKBR3 cell viability by MTS assay. (B) Morphology of MCF-10A and MDA-MB-231 was observed under microscope following treatment with SH-479 for 72 h. Scale bar, 100 µm. Data were presented as the means ± standard deviation of three individual experiments. **P<0.01 and ***P<0.001.
fluorescence indicates the nucleus (Fig. 3B). Because SH-479 can inhibit TNBC cell viability, cell cycle and apoptosis were determined. The expression of cyclin E starts in the middle phase of G1 phase and gradually decreases after reaching the peak in G1/S phase. Cyclin E is therefore the key protein of G1 to S phase. The results demonstrated that SH-479 had no effect on cell cycle transition from G1 phase to S phase. There was no change in the expression of proteins involved in cell cycle and apoptosis in MDA-MB-231 cells treated with SH-479 (Fig. 3C). In order to further verify the effect of SH-479 on MDA-MB-231 cell cycle, cell cycle was determined by flow cytometry. The results demonstrated that after 12 h treatment with 5 µM SH-479, the cell cycle of MDA-MB-231 cells was not modified (Fig. 3D).

SH-479 inhibits breast cancer cell migratory ability and breast cancer cell-induced osteoclast differentiation. The incidence of bone metastases in breast cancer is high, and TNBC usually leads to osteolytic bone metastasis. In the present study, MDA-MB-231 cell treatment with SH-479 induced a significant decrease in cell migratory ability in a dose-dependent manner (Fig. 4A). Furthermore, SH-479 treatment led to a decrease in the capacity of MDA-MB-231 cells to induce osteoclast differentiation in a dose-dependent manner (Fig. 4B).

Effects of SH-479 on bone marrow immune microenvironment. When bone metastasis occurs in patients with breast cancer, immune cells in the bone marrow microenvironment play an important role in the colonization and development of cancer cells. The results from the present study demonstrated that the number of CD3+CD4+T lymphocytes in the bone marrow microenvironment was significantly increased following treatment with SH-479 for 48 h (Fig. 5A). Furthermore, the number of MDSCs in the bone marrow microenvironment also serves a role in breast cancer metastasis to bones, and it can indirectly promote the development of breast cancer cells in the bone microenvironment by inhibiting the function of immune cells. The results from the present study demonstrated that SH-479 treatment decreased the number of MDSCs in bone microenvironment (Fig. 5B).

Discussion

TNBC is one subtype of breast cancer that lacks specific therapeutic targets. TNBC is characterized by a strong
invasiveness and a poor prognosis. In the present study, SH-479 had small inhibitory effect on normal breast cell MCF-10A but had a significant inhibitory effect on the viability of MDA-MB-231 cells, which was not the case for the other types of breast cancer cells. SH-479 had no effect on the morphology of the normal breast tissue cells MCF-10, however, when MDA-MB-231 cells were treated with SH-749, cells seemed to shrink.

At present, conventional chemotherapy remains the main method of treatment for TNBC; however, drug resistance is likely to occur. Combined immunotherapy may be interesting for the treatment of TNBC (14). Immunotherapy provides good results on numerous types of cancer, including melanoma, lymphoma and prostate cancer (33). Due to the lack of therapeutic targets for TNBC, it is difficult for traditional treatments to achieve ideal therapeutic effect. Previous studies have reported that PD-L1 is highly expressed in TNBC and that it is associated with increased T lymphocyte infiltration (34-36). Regarding tumor treatment with immunotherapy, a class of MDSCs with immunosuppressive effect deserves some attention. MDSCs in the tumor microenvironment can reduce the innate immunity and adaptive immunity by inhibiting the proliferation of T lymphocyte and NK cells (37,38).
The present study demonstrated that SH-479 could reduce the proportion of MDSC in the bone marrow, which may stimulate the immune system to inhibit tumor growth. However, the therapeutic effect of SH-479 on breast cancer bone metastasis requires further in vivo investigation.

The role of BA in cancer is mainly due to the induction of cell apoptosis and changes in cell cycle (39,40). In the present study, the apoptotic proteins PARP and cleaved PARP were detected by western blotting. No significant effect of SH-479 on PARP and cleaved PARP expression was observed. In addition, no significant cell death was observed in MDA-MB-231 cells following treatment with SH-479. The results from flow cytometry demonstrated that SH-479 had no significant effect on cell cycle. Microfilaments play an important role in tumor cell migration and are involved in cell migratory ability, suggesting that they may serve a crucial role in the occurrence of cancer metastasis (39,41). In the present study, SH-479 treatment altered the microfilament structure of MDA-MB-231 cells and inhibited the migratory ability of MDA-MB-231 cells, suggesting that impaired migratory ability may be related to microfilament interference in these cells. Cell microfilaments play an important role in cell proliferation and form contraction rings with myosin during mitosis (42-44). Following treatment with SH-479, MDA-MB-231 cell proliferation was inhibited, which may be related to cell microfilament interference. Because SH-479 is the ligand of the G protein-coupled bile acid receptor 1, it plays a regulatory role through G-protein-coupled receptors (GPCRs) (31). Previous studies have reported that GPCR can regulate F-actin by regulating Hippo signaling pathway and YAP/TAZ activity. The Hippo pathway is highly conserved in mammals. MST1/2 (Hpo orthologs), Sav1, Lats1/2 (Wts orthologs) and Mob1 (MOBKL1A and MOBKL1B, Mats orthologs) form a kinase cascade that phosphorylates and inhibits YAP/TAZ (Yki orthologs). YAP/TAZ in conjunction with TEAD1-4 (Sd orthologs) mediate major physiological functions of the Hippo pathway (45-49). The Hippo signaling pathway can be used as a theoretical basis for further research. The activation of osteoclasts plays an important role in the process of breast cancer metastasis to bone. Tumor cells can activate osteoclasts directly or indirectly by secreting cytokines. The growth factors released by osteoclasts after absorbing bone tissue can promote the proliferation of tumor cells and therefore lead to a vicious circle (50). We previously demonstrated that SH-479 could directly inhibit osteoclast differentiation (23). The present study showed that SH-479 had the ability to inhibit osteoclast differentiation induced by tumor cells, suggesting that it may therefore have potential therapeutic effects on breast cancer metastasis of the bone.

In conclusion, the present study demonstrated that SH-479 inhibited the activity of TNBC cells, the migratory ability of TNBC cells and the differentiation of osteoclasts induced by TNBCs. It was also demonstrated to enhance the immune microenvironment of bone marrow. These findings indicate that SH-479 may have a potential therapeutic significance for breast cancer metastasis of the bone.

Acknowledgements

Not applicable.

Funding

This study was funded by the Science and Technology Commission of Shanghai Municipality (grant no. 17411950301) and the Science and Technology Commission of Shanghai Municipality (grant no. 17ZR1439000).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JX, JZ, ZL and HW designed the study and HW approved the final version to be submitted. LT, SL, TH, WG and YX performed experiments, acquired data and drafted the manuscript. ZW, MQ, XG, XL and TW analyzed and interpreted the data. YX, XG, TW, TH, XL, XG and WG revised the manuscript for intellectual content. All authors read and approved the final manuscript. LT and HW confirmed the authenticity of all the raw data.

Ethics approval and consent to participate

The study was approved by the Animal Experiment Ethics Committee of East China Normal University (approval no. m20151002).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Beiki O, Hall P, Ekbom A and Moradi T: Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: A population-based cohort study. Breast Cancer Res 14; R5, 2012.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits of human breast tumours. Nature 406: 746-752, 2000.
3. Buijs JT and van der Pluijm G: Osteotropic cancers: From primary tumor to bone. Cancer Lett 273: 177-193, 2009.
4. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176, 2001.
5. Fang J and Xu Q: Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clin Transl Oncol 17: 173-179, 2015.
6. Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL and Clemons M: Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre. J Bone Oncol 2: 137-144, 2013.
7. Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S and Purushotham A: Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol 38: 427-434, 2014.
8. Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23: 7350-7360, 2005.
9. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Colllichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
of nuclear factor-kappaB-regulated gene products involved in
signalling. Nature 470: 548‑553, 2011.

Sawant A and Ponnazhagan S: Myeloid‑derived suppressor cells
stimulate mammary cancer metastasis through RANKL‑RANK
stimulation and bone resorption. J Med Chem 55: 3122‑3134, 2012.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ,
Santos R, Câmara CA, Filho JM, Giulietti‑Harley AM, Ribeiro Dos
de Sá MS, Costa JF, Krettli AU, Zalis MG, Maia GL, Sette IM,
impact in diabetes. J Med Chem 53: 178‑190, 2010.

Elvassore N, Dupont S and Piccolo S: A mechanical checkpoint
controls multicellular growth through YAP/TAZ regulation by
controls actin‑processing factors. Genes Dev 27: 355‑371, 2013.

Yu FX and Guan KL: The Hippo pathway: Regulators and
actin crosstalk in cell migration and division. Cytoskeleton
(Hoboken) 71: 1‑23, 2014.

Goode BL and Eck MJ: Mechanism and function of formins in the
control of actin assembly. Annu Rev Biochem 76: 593‑627, 2007.

Kovar DR: Molecular details of formin‑mediated actin assembly.
Curr Opin Cell Biol 18: 11‑17, 2006.

Aragona M, Panciera T, Manfrin A, Giuliatti S, Michielin F,
elliassore N, Dupont S and Piccolo S: A mechanich checkpoint
controls multipocrine growth through YAP/TAZ regulation by
actin‑processing factors. Cell 154: 1047‑1059, 2013.

Yu FX and Guan KL: The Hippo pathway: Regulators and
regulations. Genes Dev 27: 355‑371, 2013.

Zhang Y, Xiao Y, Dong Q, Ouyang W and Qin Q: Neferine in
regulations. Genes Dev 27: 355‑371, 2013.

Petrie RJ and Yamada KM: At the leading edge of three‑dimen
sional cell migration. J Cell Sci 125: 5917‑5926, 2012.

Akhshi TK, Wernike D and Pickny A: Microtubules and actin crosstalk in cell migration and division. Cytoskeleton
(Hoboken) 71: 1‑23, 2014.

Goode BL and Eck MJ: Mechanism and function of formins in the
control of actin assembly. Annu Rev Biochem 76: 593‑627, 2007.

Kovar DR: Molecular details of formin‑mediated actin assembly.
Curr Opin Cell Biol 18: 11‑17, 2006.

Aragona M, Panciera T, Manfrin A, Giuliatti S, Michielin F,
elliassore N, Dupont S and Piccolo S: A mechanich checkpoint
controls multipocrine growth through YAP/TAZ regulation by
actin‑processing factors. Cell 154: 1047‑1059, 2013.

Yu FX and Guan KL: The Hippo pathway: Regulators and
regulations. Genes Dev 27: 355‑371, 2013.

Zhang Y, Xiao Y, Dong Q, Ouyang W and Qin Q: Neferine in
the Lotus Plamulate Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro. J Food
Sci 84: 904‑910, 2019.

Pan D: The hippo signaling pathway in development and
Cancer Cell 27: 450‑461, 2015.

Pusztai L and Rimm DL: In situ tumor PD‑L1 mRNA expression is
associated with increased TILs and better outcome in breast
carcinomas. Clin Cancer Res 20: 2773‑2782, 2014.

Sinha P, Clements VK and Ostrand‑Rosenberg S: Reduction of
myeloid‑derived suppressor cells and induction of M1
macrophages facilitate the rejection of established metastatic
disease. J Immunol 174: 636‑645, 2005.

Friedl P and Alexander S: Cancer invasion and the microenvi
ronment: Plasticity and reciprocity. Cell 147: 992‑1009, 2011.

Mullauer FB, Kessler JH and Medema JP: Betulinic acid, a
natural compound with potent anticancer effects. Anticancer
Res 22: 215‑227, 2010.

McArthur HL and Page DB: Immune therapy for the treatment of
breast cancer: Checkpoint blockade, cancer vaccines, and future
directions in combination immunotherapy. Clin Adv Hematol
Oncol 14: 922‑933, 2016.

Schalper KA, Velcheti V, Carvajal D, Wimerly B, Brown J,
Pusztai L and Rimm DL: In situ tumor PD‑L1 mRNA expression is
associated with increased TILs and better outcome in breast
carcinomas. Clin Cancer Res 20: 2773‑2782, 2014.

Sinha P, Clements VK and Ostrand‑Rosenberg S: Reduction of
myeloid‑derived suppressor cells and induction of M1
macrophages facilitate the rejection of established metastatic
disease. J Immunol 174: 636‑645, 2005.

Friedl P and Alexander S: Cancer invasion and the microenvi
ronment: Plasticity and reciprocity. Cell 147: 992‑1009, 2011.

Mullauer FB, Kessler JH and Medema JP: Betulinic acid, a
natural compound with potent anticancer effects. Anticancer
Res 22: 215‑227, 2010.

McArthur HL and Page DB: Immune therapy for the treatment of
breast cancer: Checkpoint blockade, cancer vaccines, and future
directions in combination immunotherapy. Clin Adv Hematol
Oncol 14: 922‑933, 2016.

Schalper KA, Velcheti V, Carvajal D, Wimerly B, Brown J,
Pusztai L and Rimm DL: In situ tumor PD‑L1 mRNA expression is
associated with increased TILs and better outcome in breast
Sawant A and Ponnazhagan S: Myeloid‑derived suppressor cells
as osteoclast progenitors: A novel target for controlling osteolectic
bone metastasis. Cancer Res 73: 4606‑4610, 2013.

Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M
and Aggarwal BB: Anacardic acid (6‑nonanoyl salicylic acid), an
inhibitor of histone acetyltransferases, suppresses expression of
nuclear factor‑kappaB‑regulated gene products involved in
cell survival, proliferation, invasion, and inflammation through
inhibition of the inhibitory subunit of nuclear factor‑kappaB
kinase, leading to potentiation of apoptosis. Blood 111: 4880‑4891,
2008.